

UNITED STATESPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 08/591,447 04/18/96 QUENTIN-MILLET М XI/P02956US0 **EXAMINER** 020306 HM12/0103 MCDONNELL BOEHNEN HULBERT & BERGHOFF PAK, M 300 SOUTH WACKER DRIVE ART UNIT PAPER NUMBER CHICAGO IL 60606


1646

DATE MAILED:

01/03/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Office Action Summary

Application No. 08/591,447 Applicant(s)

Quentin-Millet et al.

Examiner

Michael Pak

Group Art Unit 1646



This action is FINAL.	
Since this application is in condition for allowance except for formal r in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11	1; 453 O.G. 213.
shortened statutory period for response to this action is set to expire longer, from the mailing date of this communication. Failure to responsible plication to become abandoned. (35 U.S.C. § 133). Extensions of time CFR 1.136(a).	nd within the period for response will cause the
sposition of Claims	
X Claim(s) 83-133	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
X Claim(s) 107, 114, 115, and 125	is/are allowed.
X Claim(s) 83-106, 108-113, 116-124, and 126-133	
Claim(s)	
☐ Claimsare	
oplication Papers	• ,
See the attached Notice of Draftsperson's Patent Drawing Review	v, PTO-948.
☐ The drawing(s) filed on is/are objected to by	
The proposed drawing correction, filed on is	s 🗀 pproved 🗀 disapproved.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
iority under 35 U.S.C. § 119	5 U.S.C. & 119(a)_(d)
 ☐ Acknowledgement is made of a claim for foreign priority under 3! ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority 	
received.	inty documents have seen
☐ received. ☐ received in Application No. (Series Code/Serial Number)	
received in Application No. (comes cooks) and the internat	
*Certified copies not received:	
Acknowledgement is made of a claim for domestic priority unde:	35 U.S.C. § 119(e).
ttachment(s)	
☐ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)	·
☐ Interview Summary, PTO-413	
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948☐ Notice of Informal Patent Application, PTO-152	

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Serial Number: 08/591,447

Art Unit: 1646

DETAILED ACTION

Response to Amendment

- 1. The amendment filed 28 March 2000 (paper No. 32) has been entered.
- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Applicant's arguments filed 28 March 2000 (paper No. 32), have been fully considered but they are not found persuasive.

Claim Objections

4. Claims 108-113, 116, and 126-131 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Claim Rejections - 35 USC § 112

5. Claims 83-106, 108-113, 116-124, and 126-131 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a Tbp2 receptor consisting of SEQ ID

Serial Number: 08/591,447

Art Unit: 1646

NO:2 and 4 or fragments thereof, does not reasonably provide the full scope of enablement for derivatives of Tbp2 receptor. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Claims 83-106, 108-113, 116-124, and 126-131 encompass Tbp2 derivatives and variants because of the polypeptides are alignment protein with deletion in corresponding region which are clearly delineated. However, the specification fails to teach how to use the derivatives of Tbp2. One skilled in the art cannot predict whether such polypeptides would have any relationship to the TBP2 polypeptide. The state of the art is such that one skilled in the art cannot predict the tertiary structure of protein based on the primary amino acid sequence (Bowie et al.(S)). Thus, it would require undue experimentation to make and use variants with amino acid substitutions in the Tbp2 receptor because one skilled in the art could not predict the effect of the changes due to substitutions on the tertiary structure of the Tbp2 receptor which is necessary to determine if the protein is functional. Furthermore, changes tertiary structure will affect any antibody based on the original epitope of the natural Tbp2 protein found in the bacteria and if the antibody does not recognize the natural Tbp2 protein in the bacteria it cannot be used in diagnostic assay or for

Serial Number: 08/591,447

Art Unit: 1646

period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak, whose telephone number is $(703)\ 305-7038$. The examiner can normally be reached on Monday through Friday from 8:30 AM to 2:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Michael Pak

Primary Patent Examiner

Art Unit 1646

29 December 2000

Michael D. Pox



Creation date: 07-15-2005

Indexing Officer: LCHEO - LEE CHEO

Team: OIPEBackFileIndexing

Dossier: 08591447

Legal Date: 04-03-2001

No.	Doccode	Number of pages
1	A	2
2	CLM	1
3	REM	2

	CLIVI		
3	REM	2	
Total	number of pages: 5		

rotar namber et pageer e

Remarks:

Order of re-scan issued on